- Home
- JAKK vs MNPR Comparison
JAKK vs MNPR Comparison
Compare JAKK & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAKK
- MNPR
- Stock Information
- Founded
- JAKK 1995
- MNPR 2014
- Country
- JAKK United States
- MNPR United States
- Employees
- JAKK N/A
- MNPR N/A
- Industry
- JAKK Recreational Games/Products/Toys
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- JAKK Consumer Discretionary
- MNPR Health Care
- Exchange
- JAKK Nasdaq
- MNPR Nasdaq
- Market Cap
- JAKK 231.8M
- MNPR 248.8M
- IPO Year
- JAKK 1996
- MNPR 2019
- Fundamental
- Price
- JAKK $17.88
- MNPR $49.22
- Analyst Decision
- JAKK Strong Buy
- MNPR Strong Buy
- Analyst Count
- JAKK 4
- MNPR 11
- Target Price
- JAKK $40.25
- MNPR $68.60
- AVG Volume (30 Days)
- JAKK 82.1K
- MNPR 39.3K
- Earning Date
- JAKK 10-29-2025
- MNPR 11-07-2025
- Dividend Yield
- JAKK 5.61%
- MNPR N/A
- EPS Growth
- JAKK 25.15
- MNPR N/A
- EPS
- JAKK 3.34
- MNPR N/A
- Revenue
- JAKK $684,694,000.00
- MNPR N/A
- Revenue This Year
- JAKK N/A
- MNPR N/A
- Revenue Next Year
- JAKK $4.01
- MNPR N/A
- P/E Ratio
- JAKK $5.33
- MNPR N/A
- Revenue Growth
- JAKK 1.31
- MNPR N/A
- 52 Week Low
- JAKK $16.24
- MNPR $2.40
- 52 Week High
- JAKK $35.79
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- JAKK 50.93
- MNPR 67.11
- Support Level
- JAKK $17.27
- MNPR $42.51
- Resistance Level
- JAKK $18.00
- MNPR $45.78
- Average True Range (ATR)
- JAKK 0.37
- MNPR 3.42
- MACD
- JAKK 0.06
- MNPR 1.71
- Stochastic Oscillator
- JAKK 48.80
- MNPR 97.14
About JAKK JAKKS Pacific Inc.
Jakks Pacific Inc is a multi-product line, multi-brand toy company that designs, produces, markets, sells and distributes toys and related kid-targeted consumer products, inclusive of kids indoor and outdoor furniture, costumes and various product lines in the sporting goods and home furnishings space. Its products offering include Traditional toys and electronics such as Action figures, Toy vehicles, Dolls and accessories, Ride-on toys, Toys for pets, and others. The company's products have been divided into two segments: (i) Toys/Consumer Products and (ii) Costumes.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.